120 related articles for article (PubMed ID: 17324341)
1. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.
Holtan SG; Porrata LF; Micallef IN; Padley DJ; Inwards DJ; Ansell SA; Johnston PB; Gastineau DA; Markovic SN
Clin Lymphoma Myeloma; 2007 Jan; 7(4):315-8. PubMed ID: 17324341
[TBL] [Abstract][Full Text] [Related]
2. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
[TBL] [Abstract][Full Text] [Related]
3. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.
Joao C; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Markovic SN
Bone Marrow Transplant; 2006 May; 37(9):865-71. PubMed ID: 16532015
[TBL] [Abstract][Full Text] [Related]
4. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma.
Holtan SG; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Litzow MR; Gastineau DA; Markovic SN
Br J Haematol; 2006 Jun; 133(6):628-33. PubMed ID: 16704437
[TBL] [Abstract][Full Text] [Related]
5. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Porrata LF; Gertz MA; Inwards DJ; Litzow MR; Lacy MQ; Tefferi A; Gastineau DA; Dispenzieri A; Ansell SM; Micallef IN; Geyer SM; Markovic SN
Blood; 2001 Aug; 98(3):579-85. PubMed ID: 11468153
[TBL] [Abstract][Full Text] [Related]
6. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
7. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma.
Yoong Y; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Litzow MR; Gertz MA; Lacy MQ; Dispenzieri A; Gastineau DA; Tefferi A; Elliott M; Snow DS; Hogan WJ; Markovic SN
Leuk Lymphoma; 2005 Sep; 46(9):1287-94. PubMed ID: 16109605
[TBL] [Abstract][Full Text] [Related]
8. Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.
Gazitt Y; Freytes CO; Akay C; Badel K; Calandra G
Stem Cells Dev; 2007 Aug; 16(4):657-66. PubMed ID: 17784839
[TBL] [Abstract][Full Text] [Related]
9. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Litzow MR; Winters JL; Markovic SN
Biol Blood Marrow Transplant; 2008 Jul; 14(7):807-16. PubMed ID: 18541201
[TBL] [Abstract][Full Text] [Related]
10. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target.
Katipamula R; Porrata LF; Gastineau DA; Markovic SN; Moore SB; Greiner C; Burgstaler EA; Padley DJ; Winters JL
Bone Marrow Transplant; 2006 May; 37(9):811-7. PubMed ID: 16532018
[TBL] [Abstract][Full Text] [Related]
11. Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.
Porrata LF; Burgstaler EA; Winters JL; Jacob EK; Gastineau DA; Suman VJ; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nevala W; Markovic SN
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1017-1023. PubMed ID: 26826432
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of early lymphocyte recovery after post-autografting administration of GM-CSF in non-Hodgkin's lymphoma.
Tiwari D; Gao F; Hidalgo J; Adkins DR; Vij R; DiPersio JF; Khoury HJ
Bone Marrow Transplant; 2007 Oct; 40(7):671-5. PubMed ID: 17680023
[TBL] [Abstract][Full Text] [Related]
13. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G;
J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922
[TBL] [Abstract][Full Text] [Related]
14. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.
Varmavuo V; Rimpiläinen J; Kuitunen H; Nihtinen A; Vasala K; Mikkola M; Kutila A; Lehtonen P; Kuittinen T; Mäntymaa P; Nousiainen T; Kuittinen O; Jantunen E
Transfusion; 2014 May; 54(5):1243-50. PubMed ID: 24118008
[TBL] [Abstract][Full Text] [Related]
15. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma.
Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Moreb JS
Bone Marrow Transplant; 2003 Jun; 31(11):1009-13. PubMed ID: 12774052
[TBL] [Abstract][Full Text] [Related]
16. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation.
Porrata LF; Gastineau DA; Padley D; Bundy K; Markovic SN
Leuk Lymphoma; 2003 Jun; 44(6):997-1000. PubMed ID: 12854901
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma.
Kim Y; Kim SJ; Cheong JW; Cho H; Chung H; Lee JY; Jang JE; Min YH; Kim JS
Hematol Oncol; 2017 Dec; 35(4):465-471. PubMed ID: 27440113
[TBL] [Abstract][Full Text] [Related]
19. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
[TBL] [Abstract][Full Text] [Related]
20. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]